专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08609616B2 Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions 失效
标题翻译：用于预防或治疗坏死性骨质状况的含锶化合物
公开(公告)号：US08609616B2
公开(公告)日：2013-12-17
申请号：US13182798
申请日：2011-07-14
申请人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Henry G Bone, III
发明人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Henry G Bone, III
IPC分类号： A61P19/08
CPC分类号： A61K33/24 , A61K31/28 , A61K31/56 , A61K31/57 , A61K31/663 , A61K45/06 , A61K2300/00
摘要： A method for the treatment and/or prophylaxis of an osteonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).
摘要翻译：用于治疗和/或预防有需要的哺乳动物中的骨坏死性骨病的方法，例如特发性或继发性骨坏死，无血管性骨坏死，糖皮质激素诱导的骨缺血/骨坏死，Legg-Calve-Perthes疾病和股骨头坏死，所述方法包括向哺乳动物施用有效剂量的含锶化合物（a）。用于治疗和/或预防将要或被治疗的哺乳动物中的骨坏死性骨病，例如特发性或继发性骨坏死，无血管性骨坏死，糖皮质激素诱导的骨缺血/骨坏死和股骨头坏死的方法具有已知或怀疑诱导骨细胞凋亡和/或坏死的治疗剂（b），该方法包括与（b）组合施用含锶化合物（a）。

2. 发明申请

US20100143473A1 COMBINATION TREATMENT WITH STRONTIUM FOR THE PROPHYLAXIS AND/OR TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS 失效
标题翻译：用于治疗和/或治疗骨质疏松症和/或骨质疏松症的瘢痕组合治疗
公开(公告)号：US20100143473A1
公开(公告)日：2010-06-10
申请号：US12434971
申请日：2009-05-04
申请人： Christian Hansen , Henrik Nilsson , Stephan Christgau
发明人： Christian Hansen , Henrik Nilsson , Stephan Christgau
IPC分类号： A61K33/00 , A61K33/16 , A61K33/18 , A61K33/42 , A61K31/19 , A61K33/06 , A61K31/59 , A61K31/593 , A61K31/592 , A61K38/29 , A61P19/00 , A61K9/28
CPC分类号： A61K33/06 , A61K31/592 , A61K31/593 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and/or increasing bone density and/or improving healing of fractured bone and/or improving bone quality are administered for use in the treatment and/or prophylaxis of cartilage and/or bone conditions.
摘要翻译：联合治疗，其中施用含锶化合物以及能够降低骨折发生率和/或增加骨密度和/或改善骨折骨愈合和/或改善骨质量的一种或多种活性物质用于治疗和/或预防软骨和/或骨骼状况。

3. 发明申请

US20100048697A1 WATER-SOLUBLE STRONTIUM SALTS FOR USE IN TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS 失效
标题翻译：用于治疗骨质疏松症和/或骨质疏松症的水溶性UM条
公开(公告)号：US20100048697A1
公开(公告)日：2010-02-25
申请号：US12535053
申请日：2009-08-04
申请人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Jens E.T. Andersen
发明人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Jens E.T. Andersen
IPC分类号： A61K31/28
CPC分类号： A61K33/24 , C07C55/08 , C07C55/10 , C07C57/145 , C07C59/08 , C07C59/19 , C07C59/347
摘要： Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.
摘要翻译：用于治疗和/或预防软骨和/或骨骼状况的化合物和药物组合物以及治疗这种病症的方法。化合物是在室温下具有约1g / l至约100g / l水溶性的锶盐，特别是锶的锶或二羧酸盐的氨基酸盐。新的水溶性锶盐的实例是例如。谷氨酸锶和α-酮戊二酸锶。本发明还涉及一种制备谷氨酸锶盐的改进方法。

4. 发明授权

US07595342B2 Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions 失效
标题翻译：用于治疗软骨和/或骨骼状况的水溶性锶盐
公开(公告)号：US07595342B2
公开(公告)日：2009-09-29
申请号：US11269289
申请日：2005-11-07
申请人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Jens E.T. Andersen
发明人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Jens E.T. Andersen
IPC分类号： A61K31/19
CPC分类号： A61K33/24 , C07C55/08 , C07C55/10 , C07C57/145 , C07C59/08 , C07C59/19 , C07C59/347
摘要： Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.
摘要翻译：用于治疗和/或预防软骨和/或骨骼状况的化合物和药物组合物以及治疗这种病症的方法。化合物是在室温下具有约1g / l至约100g / l水溶性的锶盐，特别是锶的锶或二羧酸盐的氨基酸盐。新的水溶性锶盐的实例是例如。谷氨酸锶和α-酮戊二酸锶。本发明还涉及一种制备谷氨酸锶盐的改进方法。

5. 发明申请

US20060122274A1 Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions 失效
公开(公告)号：US20060122274A1
公开(公告)日：2006-06-08
申请号：US11269289
申请日：2005-11-07
申请人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Jens Andersen
发明人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Jens Andersen
IPC分类号： A61K31/198 , C07F3/02
CPC分类号： A61K33/24 , C07C55/08 , C07C55/10 , C07C57/145 , C07C59/08 , C07C59/19 , C07C59/347
摘要： Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

6. 发明授权

US08623422B2 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions 失效
标题翻译：用于锶的组合治疗用于预防和/或治疗软骨和/或骨条件
公开(公告)号：US08623422B2
公开(公告)日：2014-01-07
申请号：US12434971
申请日：2009-05-04
申请人： Christian Hansen , Henrik Nilsson , Stephan Christgau
发明人： Christian Hansen , Henrik Nilsson , Stephan Christgau
IPC分类号： A61K33/00 , A61P19/08 , A61P19/10
CPC分类号： A61K33/06 , A61K31/592 , A61K31/593 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and/or increasing bone density and/or improving healing of fractured bone and/or improving bone quality are administered for use in the treatment and/or prophylaxis of cartilage and/or bone conditions.
摘要翻译：联合治疗，其中施用含锶化合物以及能够降低骨折发生率和/或增加骨密度和/或改善骨折骨愈合和/或改善骨质量的一种或多种活性物质用于治疗和/或预防软骨和/或骨骼状况。

7. 发明授权

US08541471B2 Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions 失效
公开(公告)号：US08541471B2
公开(公告)日：2013-09-24
申请号：US12535053
申请日：2009-08-04
申请人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Jens E. T. Andersen
发明人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Jens E. T. Andersen
IPC分类号： A61K31/19
CPC分类号： A61K33/24 , C07C55/08 , C07C55/10 , C07C57/145 , C07C59/08 , C07C59/19 , C07C59/347
摘要： Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

8. 发明申请

US20090035315A1 Method of Improving Treatments in Rheumatic and Arthritic Diseases 审中-公开
标题翻译：改善风湿性关节炎疾病治疗方法
公开(公告)号：US20090035315A1
公开(公告)日：2009-02-05
申请号：US11629613
申请日：2005-06-17
申请人： Stephan Christgau , Christian Hansen , Henrik Nilsson
发明人： Stephan Christgau , Christian Hansen , Henrik Nilsson
IPC分类号： A61K39/395 , A61K31/662 , A61K31/351 , A61K31/715 , A61K31/724 , A61K31/192 , A61K31/18 , A61K31/167 , A61K31/60 , A61K31/235 , A61K31/5415 , A61K31/56 , A61K38/00 , A61K31/415
CPC分类号： A61K31/519 , A61K31/28 , A61K31/403 , A61K31/573 , A61K31/65 , A61K31/663 , A61K31/7008 , A61K31/737 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and/or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, opioids, inhibitors/antagonists of IL-1, inhibitors/antagonists of TNF-alpha, inhibitors of matrix metallo-proteinases (MMPs), cathepsin K inhibitors, inhibitors/antagonists of RANK-ligand, statins, glucocorticoids, chondroitin sulphate, NMDA receptor antagonists, inhibitors of interleukin-I converting enzyme, Calcitonin gene related peptide antagonists, glycine antagonists, vanilloid receptor antagonists, inhibitors of inducible nitric oxide synthetase (iNOS), N-acetylcholine receptor agonists, neurokinin antagonists, neuroleptic agents, PAR2 receptor antagonists and anabolic growth factors acting on joint tissue components. Pharmaceutical compositions comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance as defined above.
摘要翻译：改善关节疾病的治疗，例如，骨关节炎和类风湿性关节炎以及疼痛，其中单独施用含锶化合物或与一种或多种第二治疗和/或预防活性物质组合施用，所述第二治疗和/或预防活性物质选自二膦酸盐，葡糖胺，扑灭剂，止痛剂，疾病修饰抗风湿化合物（DMARD），选择性雌激素受体调节剂（SERM），芳香酶抑制剂，非甾体抗炎药（NSAID），COX-2抑制剂，COX-3抑制剂，阿片样物质，IL-1抑制剂/拮抗剂，TNF-α的抑制剂/拮抗剂，基质金属蛋白酶（MMPs）的抑制剂，组织蛋白酶K抑制剂，RANK-配体的抑制剂/拮抗剂，他汀类，糖皮质激素，硫酸软骨素，NMDA受体拮抗剂，白细胞介素-I转化酶抑制剂，降钙素基因相关肽拮抗剂，甘氨酸拮抗剂，香草素受体拮抗剂，诱导型一氧化氮合成酶抑制剂（iNOS），N-乙酰胆碱受体激动剂，神经激肽拮抗剂，精神抑制剂，PAR2受体拮抗剂和作用于关节组织成分的合成代谢生长因子。包含含锶化合物和如上定义的第二治疗和/或预防活性物质的药物组合物。

9. 发明申请

US20060275503A1 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions 审中-公开
标题翻译：用于锶的组合治疗用于预防和/或治疗软骨和/或骨骼状况
公开(公告)号：US20060275503A1
公开(公告)日：2006-12-07
申请号：US10556149
申请日：2004-05-06
申请人： Christian Hansen , Henrik Nilsson , Stephan Christgau
发明人： Christian Hansen , Henrik Nilsson , Stephan Christgau
IPC分类号： A61K33/24 , A61K33/06
CPC分类号： A61K33/06 , A61K31/592 , A61K31/593 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and/or increasing bone density and/or improving healing of fractured bone and/or improving bone quality are administered for use in the treatment and/or prophylaxis of cartilage and/or bone conditions.
摘要翻译：联合治疗，其中施用含锶化合物以及能够降低骨折发生率和/或增加骨密度和/或改善骨折骨愈合和/或改善骨质量的一种或多种活性物质用于治疗和/或预防软骨和/或骨骼状况。

10. 发明申请

US20090191282A1 CONTROLLED RELEASE COMPOSITION CONTAINING A STRONTIUM SALT 审中-公开
标题翻译：含锶盐的控制释放组合物
公开(公告)号：US20090191282A1
公开(公告)日：2009-07-30
申请号：US12341439
申请日：2008-12-22
申请人： Christian Hansen , Henrik Nilsson , Jens E.T. Andersen , Stephan Christgau
发明人： Christian Hansen , Henrik Nilsson , Jens E.T. Andersen , Stephan Christgau
IPC分类号： A61K33/14 , A61K31/19 , A61K31/195 , A61K31/194 , A61P19/00 , A61K33/06 , A61K31/59
CPC分类号： A61K33/00 , A61K31/28 , A61K31/592 , A61K31/593 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for preventing a cartilage and/or bone condition in a subject, and for the treatment and/or prophylaxis of secondary osteoporosis.
摘要翻译：包含锶盐的控释药物组合物。本发明还涉及锶盐用于治疗患有软骨和/或骨的代谢和/或结构完整性的疾病和病症的男性。本发明还涉及含锶化合物用于预防受试者的软骨和/或骨骼状况以及用于治疗和/或预防继发性骨质疏松症的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式